Depression and Alcohol Use Disorder: A Clinical Deep-Dive

Overview

Depression and alcohol use disorder (AUD) are two of the most common mental health conditions in the world — and when they occur together, the clinical picture becomes significantly more complex and more dangerous. The decisions that matter most hinge on three questions: Which came first? Is the depression a direct result of heavy drinking, or is it an independent condition that exists alongside it? And how should treatment be sequenced or combined?

Getting those questions right changes everything. A person whose depression is caused by alcohol may not need antidepressants at all — sustained abstinence may resolve their symptoms. A person with independent major depressive disorder (MDD) who is also drinking heavily needs both conditions treated simultaneously, or neither will improve. Misdiagnosis in either direction causes real harm: unnecessary medication exposure on one end, undertreated depression on the other.

This article synthesizes the best available evidence on the epidemiology, mechanisms, diagnosis, and treatment of depression-AUD comorbidity. It is honest about what the evidence supports, where it is weak, and where critical gaps remain.

Epidemiology

The co-occurrence of MDD and AUD is not rare — it is the rule rather than the exception in clinical populations. A foundational meta-analysis found that the presence of either disorder approximately doubles the risk of the other, with pooled adjusted odds ratios ranging from 2.00 to 2.09 ^[1]. This is a robust, replicated signal that should reshape how clinicians screen and treat both conditions.

In primary care settings, the numbers are striking. Available evidence suggests that patients who screen positive for depression have substantially higher rates of high-risk drinking than those who screen negative ^[2]. Among people who are already drinking at high-risk levels, a positive depression screen is associated with markedly elevated prevalence of probable AUD compared to those without depression ^[2]. Put plainly: if someone walks into a primary care clinic with depression, they are a high-priority target for alcohol screening — and most are not being assessed for it ^[3].

The stakes extend across the lifespan. Adolescents with concurrent depression and AUD showed dramatically elevated risks as adults: adjusted odds ratios of 5.33 for adult depressive episodes, 7.68 for adult AUD, 4.05 for anxiety disorders, and 5.37 for suicidality, compared to unaffected peers ^[4]. A substantial proportion of the adolescent comorbid group experienced both conditions as adults ^[4]. Early co-occurrence is not a phase — it is a trajectory.

The Bidirectional Relationship

The relationship between depression and AUD runs in both directions, but the evidence suggests the directions are not equally weighted.

The most plausible primary causal pathway runs from AUD increasing risk for MDD — not the reverse — likely through neurophysiological and metabolic mechanisms of alcohol exposure ^[1]. A prospective study found that AUD severity at baseline predicted incident depression in a dose-dependent fashion, while the reverse was not observed ^[5]. This matters clinically: it means that reducing drinking is not just a treatment goal in its own right — it is a direct intervention on depression risk.

That said, the relationship is genuinely bidirectional in practice. Alcohol exacerbates depressive symptoms, and depression amplifies drinking ^[6]. Depression drives drinking through self-medication, social withdrawal, low energy, and disrupted sleep. Drinking then deepens depression through neurochemical disruption, social and financial consequences, and the shame cycle that follows. Each disorder makes the other harder to treat.

Large-scale real-world data confirm this co-movement. In a primary care dataset of 198,335 patients, increases in AUDIT-C risk categories were directly associated with increases in positive depression screens — and decreases tracked together ^[7]. This bidirectional co-movement has direct implications for monitoring: when one improves, the other often follows, and when one worsens, clinicians should look immediately at the other.

The long-term prognosis without integrated treatment is poor. A 10-year prospective study found that actively alcoholic depressed patients had approximately half the likelihood of recovering from depression compared to those who were not actively alcoholic ^[8]. Every year a clinician treats depression while leaving active AUD unaddressed is a year of preventable suffering.

Alcohol-Induced vs. Independent Depression

One of the most consequential clinical distinctions in this comorbidity is whether the depression is alcohol-induced or independent of alcohol use. DSM-5 distinguishes between a substance-induced depressive disorder — where depressive symptoms are a direct physiological consequence of alcohol — and an independent MDD that co-occurs with AUD.

The evidence base for this distinction is substantial. An acamprosate meta-analysis analyzing 3,354 patients across 11 studies found that 33.4% of alcohol-dependent patients were depressed post-detoxification — and that continuous abstinence was the single strongest predictor of depression remission, with abstinent patients 7.58 times more likely to remit than those who continued drinking ^[7]. This is a powerful finding: for a large proportion of people with AUD and depressive symptoms, the depression is driven by the alcohol, and treating the alcohol treats the depression.

Trajectory data add important nuance. Latent growth curve analysis of patients in early abstinence treatment identified three distinct subgroups: a low-symptom trajectory (approximately 70-73% of patients) who showed rapid depression symptom reduction, a high-symptom trajectory (22-24%) who started high but improved, and a sustained trajectory (5-6%) who maintained high depressive symptoms throughout the entire early abstinence period ^[6]. That sustained subgroup almost certainly represents independent MDD — patients whose depression does not resolve with abstinence and who require concurrent antidepressant treatment regardless of drinking status.

The practical clinical rule: Allow a period of sustained abstinence — typically 2-4 weeks — while monitoring depressive symptoms closely. Patients whose symptoms resolve are likely experiencing alcohol-induced depression. Patients whose symptoms persist or who fall into the sustained trajectory subgroup require independent MDD treatment. Tracking PHQ-9 scores weekly during early abstinence is the most actionable way to identify which group a patient belongs to.

Screening tools themselves require adjustment in AUD populations. The optimal BDI-II cut-off in AUD patients was found to be 24.5 — higher than general population norms — suggesting that standard depression screening thresholds may underdetect depression in this group ^[9].

Why the Distinction Matters for Treatment

The alcohol-induced vs. independent MDD distinction is not academic — it directly determines the treatment plan.

For alcohol-induced depression, the primary intervention is treating the AUD. Antidepressants are not indicated as a first step, and initiating them before observing the effect of abstinence exposes patients to medication side effects and may create a false sense that the depression is being addressed when the underlying driver — alcohol — is not. The Lejoyeux data make clear that abstinence is the most potent antidepressant available for this group ^[7].

For independent MDD, both conditions require treatment simultaneously. The evidence is unambiguous that treating depression alone does not change drinking: a large RCT found that alcohol consumption did not change despite treatment effects on depression — hazardous drinkers remained hazardous drinkers after 12 weeks of depression treatment ^[10]. Treating only one condition is insufficient regardless of which one is treated first.

The clinical paradox is real: the patients who most need abstinence to resolve their depression are often the least able to achieve it without concurrent depression treatment. Depressed patients showed lower motivation and lower compliance with AUD treatment compared to non-depressed patients ^[7]. This is the core argument against a rigid sequential approach.

Antidepressant Evidence

Antidepressants are commonly used in depression-AUD comorbidity, but the evidence base is more complicated than their widespread use might suggest ^[6].

SSRIs are the most commonly prescribed antidepressants in this population. They are appropriate for independent MDD co-occurring with AUD, but their effect on alcohol use itself is modest at best when used alone ^[6]. The Pettinati 2010 sertraline trials — referenced in the clinical literature — showed that the combination of naltrexone plus sertraline outperformed either medication alone in patients with comorbid MDD and AUD, a finding that underscores the importance of targeting both conditions pharmacologically rather than relying on antidepressant monotherapy.

TCAs (tricyclic antidepressants), including desipramine, have been used in this population with modest effects ^[6]. Their use is limited by side effect profiles and overdose risk — a significant concern in a population with elevated suicide risk ^[6].

The general principle supported by the evidence: SSRIs and TCAs treat MDD; their effect on AUD outcomes is limited when used in isolation. Combining antidepressants with AUD-specific pharmacotherapy produces better outcomes than either alone ^[6].

Evidence level caveat: The corpus used in this synthesis does not contain RCT-level evidence directly comparing pharmacotherapy combinations (e.g., SSRI + naltrexone vs. SSRI alone vs. naltrexone alone) with adequate statistical power in patients with confirmed independent MDD and AUD ^[6]. The recommendation to combine treatments is supported by clinical review evidence ^[6] but lacks the head-to-head RCT data that would provide the highest confidence. This is a genuine gap.

Combining Antidepressants with AUD Pharmacotherapy

The strongest pharmacological approach for confirmed independent MDD with AUD is combining an antidepressant with an AUD-specific medication. Bahji and colleagues identify naltrexone and acamprosate as first-line AUD medications, and explicitly state that combining antidepressants with AUD medications improves treatment efficacy ^[6].

Naltrexone reduces alcohol craving and reward by blocking opioid receptors. Combined with sertraline, it outperformed either medication alone in comorbid MDD-AUD populations. It is contraindicated in patients using opioids and requires liver function monitoring.

Acamprosate reduces post-acute withdrawal symptoms and supports abstinence maintenance. The Lejoyeux meta-analysis — which demonstrated the 7.58x depression remission advantage for abstinent patients — was conducted in the context of acamprosate treatment, suggesting that acamprosate's support of abstinence may be part of the mechanism through which depression remits ^[7].

Topiramate has emerging evidence for AUD and may be combined with antidepressants, though the evidence base for this combination in comorbid populations is less developed.

The reconciled clinical framework supported by the evidence is: simultaneous treatment, with AUD pharmacotherapy as a non-negotiable component. The Lejoyeux finding tells us that abstinence is the mechanism through which depression most powerfully remits; the Bahji recommendation tells us that integrated simultaneous treatment is the delivery system most likely to achieve it. These findings are complementary, not contradictory.

Behavioral Treatments

Psychotherapy evidence for depression-AUD comorbidity is meaningful but modest in effect size.

The Grant et al. network meta-analysis of 36 RCTs (N=2,729) — the highest-quality psychotherapy evidence in the available literature — found that CBT demonstrated moderate-confidence benefit for depressive symptoms (SMD = -0.84; 95% CI, -1.05 to -0.63) and low-confidence benefit for alcohol use (SMD = -0.25; 95% CI, -0.47 to -0.04) compared to no additional treatment ^[11]. Critically, the authors had very low confidence in remission outcomes for both disorders across all interventions — a finding the field should not paper over.

The Riper et al. meta-analysis of 12 studies (N=1,721) found that combined CBT and Motivational Interviewing (MI) produced small but statistically significant effects compared to treatment-as-usual: g = 0.17 for alcohol consumption reduction and g = 0.27 for depression symptom reduction ^[12]. These are modest numbers, but they are achieved without requiring prior abstinence — which matters enormously for patients who cannot achieve abstinence before treatment begins.

Behavioral Activation (BA) deserves specific attention. Bahji and colleagues note that behavioral activation has proven effective in treating depression while reducing alcohol cravings ^[6]. The mechanism is direct: BA disrupts the avoidance-withdrawal cycle that sustains both depression and drinking simultaneously, targeting depressive anhedonia while removing the functional role alcohol plays as a coping substitute. BA is also less cognitively demanding than full CBT protocols — which matters because a substantial proportion of early-detoxified AUD inpatients show impaired performance on neuropsychological domains, particularly executive function and memory ^[13]. Standard CBT-D protocols assume cognitive capacities that may simply not be present in early recovery. BA may therefore be the preferred entry point in early abstinence, with more cognitively demanding CBT components introduced as recovery stabilizes.

Sleep

Insomnia sits at the intersection of depression, AUD, and relapse risk in a way that makes it a priority treatment target. It is simultaneously a symptom of depression, a symptom of alcohol withdrawal and post-acute withdrawal syndrome, and an independent predictor of relapse to drinking.

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for insomnia in this population. Benzodiazepines and Z-drugs (such as zolpidem) should be avoided given their abuse potential and the risk of cross-dependence in people with AUD. Addressing sleep as a distinct treatment target — rather than assuming it will resolve when depression or drinking improves — is an important component of integrated care ^[6].

Suicide Risk

The suicide risk associated with depression-AUD comorbidity is not additive — it appears multiplicative, and it demands a different level of clinical vigilance than either disorder alone.

Among individuals with AUD, 23% reported lifetime suicide attempts ^[14]. Those who attempted suicide had significantly greater rates of comorbid MDD, PTSD, and suicidal ideation, with polygenic scores for suicide attempt, depression, and PTSD associated with increased odds of lifetime attempt (ORs = 1.22–1.44) ^[14]. Nearly one in four people with AUD has attempted suicide — this is not a marginal subgroup. Clinicians treating AUD must treat this as a suicide-risk population by default.

Adolescents with concurrent depression and AUD showed 5.37 times greater odds of adult suicidality compared to unaffected peers (95% CI: 2.28–12.66) ^[4]. This risk persists across decades, not just during acute episodes.

Stigma creates a specific risk pathway. Daily diary data show that within-person fluctuations in felt depression stigma are positively associated with same-day heavy drinking and greater odds of heavy drinking ^[15]. The shame-intoxication cycle — feeling ashamed of depression, drinking to cope, feeling more ashamed — has direct suicide risk implications that treatment must address explicitly.

Care transitions are the highest-risk windows. The period following detoxification, hospital discharge, or treatment program completion is when patients are most vulnerable. The Gopaldas sustained-trajectory subgroup — the 6% who maintain high depression symptoms throughout early abstinence ^[6] — represents the patients at greatest risk during this window. Continuous monitoring, not discharge, is the appropriate response.

The system is structurally failing these patients. VA data confirm that positive alcohol screens are followed up less consistently than positive depression screens ^[3] — a dangerous asymmetry given that leaving acute intoxication unaddressed leaves the most potent near-term suicide risk amplifier entirely unmanaged. Sequential treatment that addresses depression while leaving AUD untreated does not reduce suicide risk; it leaves the loaded gun on the table.

An important gap: No document in the available evidence base directly addresses suicide risk during the integrated treatment transition itself — the period between initiating care and achieving stable remission. The Persson pilot study noted increased adverse emotional experiences during integrated treatment ^[13], and the Gopaldas sustained-trajectory data suggest some patients worsen rather than improve ^[6]. This is precisely when patients are most vulnerable, and the evidence is silent on how to monitor and protect them during that interval.

Gender Differences

Women with AUD face a particularly elevated risk profile for comorbid depression and suicidality. Alcohol-dependent women face heightened recurrent suicidal behavior risk due to psychiatric comorbidities including depression, anxiety, and PTSD, compounded by social stigma and inadequate gender-specific care ^[16]. The Persson pilot study of integrated treatment was conducted specifically in women with co-occurring depression and moderate-to-severe AUD, demonstrating feasibility and symptom reduction — though the sample size (n=7) limits conclusions ^[13].

Women are more likely to present with comorbid depression as the prominent feature of their AUD presentation, while men are more likely to present with externalizing disorders. Treatment programs that do not account for these differences risk misidentifying the clinical picture and delivering care that does not fit the person in front of them.

Primary Care and Collaborative Care

Most people with depression-AUD comorbidity first present to primary care, not to specialty mental health or addiction services. This makes primary care the most important setting for early identification and integrated treatment — and currently one of the most significant points of system failure.

The evidence is clear that joint screening is essential. The PHQ-9 (or PHQ-2 as a first step) and AUDIT-C should be co-administered routinely in primary care settings ^{[2] [7]}. The current reality is that positive depression screens are significantly more likely to trigger further assessment or referral than positive alcohol screens ^[3] — meaning patients with comorbid presentations are systematically having their depression addressed while their AUD goes unmanaged. This is de facto sequential treatment, delivered in the wrong direction.

Collaborative care models — in which a psychiatrist consultant works alongside a care manager embedded in primary care — improve outcomes for both depression and AUD by ensuring that neither condition falls through the cracks. The evidence for collaborative care in depression is strong; its application to depression-AUD comorbidity is supported by clinical review ^[6] but requires more implementation research at scale.

A lay counselor-delivered brief therapy RCT found that this approach was safe but had limited effectiveness specifically for the comorbid group ^[17], suggesting that the comorbid presentation requires more intensive or specialized delivery than brief interventions alone can provide.

Older Adults

Depression-AUD comorbidity in older adults is underrecognized and undertreated. Presentations are often atypical — fatigue, cognitive complaints, and social withdrawal may be attributed to aging rather than to a treatable comorbidity. Polypharmacy concerns are significant: interactions between antidepressants, AUD medications, and other medications common in older adults require careful management. Screening tools validated in younger populations may perform differently in older adults, and clinical thresholds may need adjustment ^[9]. This population deserves specific clinical attention that the current evidence base does not adequately address.

Veterans

Veterans represent a population with particularly high rates of depression-AUD comorbidity, often compounded by PTSD — creating a triple comorbidity that is especially difficult to treat and carries elevated suicide risk. The VA/DoD Clinical Practice Guidelines address this comorbidity, and VA data have contributed important implementation findings, including the documented gap in follow-up after positive alcohol screens compared to depression screens ^[3]. The genomic study by Barr and colleagues, which found 23% lifetime suicide attempt rates in AUD patients with comorbid MDD and PTSD ^[14], was conducted in a VA population — underscoring the severity of this triple comorbidity in veteran care settings.

Ketamine and Emerging Treatments

Ketamine and esketamine have emerged as treatments for treatment-resistant depression, and there is active research interest in their application to patients with comorbid AUD. The evidence base for ketamine specifically in depression-AUD comorbidity remains limited, and concerns exist about its abuse potential in people with AUD. Psychedelic-assisted therapy — including psilocybin — is in early research stages for both AUD and depression separately, with preliminary signals of benefit, but no robust evidence yet exists for the comorbid population. These remain areas to watch rather than current clinical recommendations.

Stigma as a Treatment Barrier

Stigma is not a background condition — it is an active treatment barrier with measurable effects on drinking behavior. Daily diary data show that within-person increases in felt depression stigma were associated with increased alcohol consumption and greater odds of heavy drinking on the same day ^[15]. This means that shame about depression actively drives drinking, and that integrated treatment must address stigma directly — not as an afterthought, but as a core component of the therapeutic work.

Drinking motives mediate the depression-alcohol relationship in ways that have direct treatment implications ^[6]. People who drink specifically to cope with depressive symptoms require interventions that address both the coping function alcohol serves and the underlying depression driving that function. Motivational Interviewing, integrated with CBT-D, is particularly well-suited to this work.

Evidence Gaps

Honest acknowledgment of what the evidence cannot yet answer is essential for clinical decision-making.

What remains unknown or underpowered:

• Combination pharmacotherapy RCTs: The corpus contains no head-to-head RCT evidence comparing SSRI + naltrexone vs. SSRI alone vs. naltrexone alone in patients with confirmed independent MDD and AUD ^[6]. The recommendation to combine treatments is supported by clinical review ^[6] but lacks the comparative trial data that would provide high confidence.

• Treatment-emergent suicide risk: No available document directly addresses suicide risk during the integrated treatment transition window — the period between initiating care and achieving stable remission. This is where patients are most vulnerable, and the evidence is silent.

• The sustained-trajectory subgroup: Approximately 5-6% of AUD patients maintain high depression symptoms throughout early abstinence ^[6]. No RCT evidence addresses whether intensified CBT-D, extended behavioral activation, or adjunctive pharmacotherapy produces better outcomes for this treatment-resistant subgroup.

• Long-term outcomes: Most studies in this corpus follow patients for 12 weeks to 12 months. Long-term integrated-care outcomes — what happens to people over years, not weeks — are largely absent.

• Optimal primary care delivery models at scale: The Persson pilot involved seven women ^[13]. The lay counselor RCT showed limited effectiveness for the comorbid group ^[17]. We have the what of integrated care; we lack the how at the system level.

• Health equity: Data on how race, socioeconomic status, and structural marginalization affect treatment access and outcomes in depression-AUD comorbidity are sparse, though some signals exist ^{[5] [18]}.

• Lived experience and recovery identity: The qualitative, longitudinal patient experience of this comorbidity — what helps people stay in treatment, what makes them leave, what recovery looks like when both disorders are in remission — is almost entirely absent from the clinical evidence base. Stigma research gestures at this ^[15], but 14-day diary studies cannot substitute for years of follow-up from the patient's perspective.

Clinical Decision Framework: A Synthesis

Drawing together the evidence across all domains, the following framework reflects the best available guidance:

1. Screen simultaneously. Every person presenting with depression should be screened for AUD, and every person presenting with AUD should be screened for depression. The PHQ-9 and AUDIT-C should be co-administered routinely ^{[2] [7]}. Use an adjusted BDI-II cut-off of 24.5 in AUD populations ^[9].

2. Distinguish alcohol-induced from independent depression. Allow a period of sustained abstinence while monitoring PHQ-9 weekly. The majority of patients (approximately 70%) will show rapid symptom reduction ^[6]. Those who do not — particularly the sustained-trajectory subgroup — require antidepressant pharmacotherapy regardless of abstinence status.

3. Treat simultaneously, with AUD pharmacotherapy as non-negotiable. Integrated treatment addressing both disorders simultaneously produces better outcomes than sequential approaches ^[6]. Abstinence is the most potent mechanism of depression remission ^[7], and integrated treatment is the delivery system most likely to achieve it. These findings are complementary.

4. Combine pharmacotherapy when independent MDD is confirmed. Naltrexone or acamprosate for AUD, combined with an SSRI or TCA for MDD, outperforms either alone ^[6]. Antidepressant monotherapy without AUD medication is insufficient.

5. Start with behavioral activation in early recovery. Cognitive impairment affects a substantial proportion of early-detoxified AUD patients ^[13]. BA is less cognitively demanding and directly targets both depressive anhedonia and alcohol's coping function. Advance to full CBT-D as cognition stabilizes.

6. Treat suicide risk as the default, not the exception. Twenty-three percent of AUD patients have a lifetime history of suicide attempts ^[14]. Care transitions — post-detox, post-discharge — are the highest-risk windows. Continuous monitoring is required, not discharge.

7. Address stigma directly. Felt depression stigma predicts same-day heavy drinking ^[15]. Shame is not a background condition — it is an active driver of the disorder that must be addressed in treatment.

The evidence is clear enough to act on, and honest enough to acknowledge its limits. For the millions of people living inside this comorbidity, the most important clinical message is also the simplest: both conditions are real, both require treatment, and treating only one is not enough.

Verified References

• ^[16] Abid-Chapon, Nelly, Rasho, Abdul Rahman, Delouvée, Sylvain (2025). "Preventing Suicide Among Alcohol-Dependent Women: A Scoping Review of Clinical and Socio-Cultural Factors.". Subst Use Misuse. DOI: 10.1080/10826084.2025.2478605 [abstract-verified: yes]
• ^[6] Bahji, Anees, Tang, Victor, Danilewitz, Marlon (2025). "Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders.". Can J Psychiatry. DOI: 10.1177/07067437251374564 [abstract-verified: partial]
• ^[14] Barr, Peter B, Neale, Zoe, Chatzinakos, Chris et al. (2025). "Clinical, Genomic, and Neurophysiological Correlates of Lifetime Suicide Attempts among Individuals with an Alcohol Use Disorder.". Complex Psychiatry. DOI: 10.1159/000543222 [abstract-verified: yes]
• ^[1] Joseph M Boden, David M Fergusson (2011). "Alcohol and depression.". Addiction (Abingdon, England). DOI: 10.1111/j.1360-0443.2010.03351.x [abstract-verified: yes]
• ^[4] Bohman, Hannes, Låftman, Sara Brolin, Alaie, Iman et al. (2025). "Adult mental health outcomes of adolescent depression and co-occurring alcohol use disorder: a longitudinal cohort study.". Eur Child Adolesc Psychiatry. DOI: 10.1007/s00787-024-02596-3 [abstract-verified: partial]
• ^[13] Caneva, Stefano, Ottonello, Marcella, Torselli, Elisa et al. (2020). "Cognitive Impairments in Early-Detoxified Alcohol-Dependent Inpatients and Their Associations with Socio-Demographic, Clinical and Psychological Factors: An Exploratory Study.". Neuropsychiatr Dis Treat. DOI: 10.2147/ndt.s254369 [abstract-verified: partial]
• ^[18] Cavazos-Rehg, Patricia A, Li, Xiao, Paraboschi, Layna et al. (2025). "Associations between microaggressions, depression, anxiety, and alcohol use among Black young adults: findings from a pilot study.". Front Public Health. DOI: 10.3389/fpubh.2025.1694000 [abstract-verified: partial]
• ^[3] Funderburk, Jennifer S, Possemato, Kyle, Maisto, Stephen A (2013). "Differences in what happens after you screen positive for depression versus hazardous alcohol use.". Mil Med. DOI: 10.7205/milmed-d-13-00165 [abstract-verified: partial]
• ^[6] Gonzalez, Vivian M, Halvorsen, Kevin A S (2021). "Mediational Role of Drinking to Cope in the Associations of Depression and Suicidal Ideation with Solitary Drinking in Adults Seeking Alcohol Treatment.". Subst Use Misuse. DOI: 10.1080/10826084.2021.1883661 [abstract-verified: partial]
• ^[6] Gopaldas, Manesh, Flook, Elizabeth A, Hayes, Nick et al. (2025). "Subgroups of anxiety and depression trajectories during early abstinence in alcohol use disorder.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.70032 [abstract-verified: partial]
• ^[11] Grant, Sean, Azhar, Gulrez, Han, Eugeniu et al. (2021). "Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis.". PLoS Med. DOI: 10.1371/journal.pmed.1003822 [abstract-verified: yes]
• ^[7] Hallgren, Kevin A, Jack, Helen E, Oliver, Malia et al. (2023). "Changes in alcohol consumption reported on routine healthcare screenings are associated with changes in depression symptoms.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.15075 [abstract-verified: partial]
• ^[5] Lasserre, Aurélie M, Imtiaz, Sameer, Roerecke, Michael et al. (2022). "Socioeconomic status, alcohol use disorders, and depression: A population-based study.". J Affect Disord. DOI: 10.1016/j.jad.2021.12.132 [abstract-verified: partial]
• ^[7] Lejoyeux, Michel, Lehert, Philippe (2011). "Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies.". Alcohol Alcohol. DOI: 10.1093/alcalc/agq077 [abstract-verified: yes]
• ^[9] Lien, Ingebjørg Aspeland, Bolstad, Ingeborg, Lien, Lars et al. (2022). "Screening for depression in patients in treatment for alcohol use disorder using the Beck Depression Inventory-II and the Hopkins Symptom Checklist-10.". Psychiatry Res. DOI: 10.1016/j.psychres.2021.114363 [abstract-verified: yes]
• ^[8] Mueller, T I, Lavori, P W, Keller, M B et al. (1994). "Prognostic effect of the variable course of alcoholism on the 10-year course of depression.". Am J Psychiatry. DOI: 10.1176/ajp.151.5.701 [abstract-verified: yes]
• ^[13] Persson, Anna, Finn, Daniel Wallhed, Broberg, Alice et al. (2025). "Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol use disorder care - a pilot study.". Front Psychiatry. DOI: 10.3389/fpsyt.2025.1473988 [abstract-verified: partial]
• ^[12] Heleen Riper, Gerhard Andersson, Sarah B Hunter et al. (2014). "Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis.". Addiction (Abingdon, England). DOI: 10.1111/add.12441 [abstract-verified: yes]
• ^[2] Ryan, Emma D, Chang, Yanni M, Oliver, Malia et al. (2022). "An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive for depression and high-risk drinking.". BMC Health Serv Res. DOI: 10.1186/s12913-022-08408-1 [abstract-verified: partial]
• ^[10] Strid, Catharina, Hallgren, Mats, Forsell, Yvonne et al. (2019). "Changes in alcohol consumption after treatment for depression: a secondary analysis of the Swedish randomised controlled study REGASSA.". BMJ Open. DOI: 10.1136/bmjopen-2018-028236 [abstract-verified: partial]
• ^[17] Synowski, Jasper, Weiss, Helen A, Velleman, Richard et al. (2021). "A lay-counsellor delivered brief psychological treatment for men with comorbid Alcohol Use Disorder and depression in primary care: Secondary analysis of data from a randomized controlled trial.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2021.108961 [abstract-verified: partial]
• ^[15] Wang, Katie, Manning, Robert B, Weiss, Nicole H et al. (2026). "Depression stigma and alcohol use among adults with major depressive disorder: a daily diary study.". Addict Behav. DOI: 10.1016/j.addbeh.2026.108737 [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[4] → ^[2] (verifier: partial; score 0.74). Title: Psychiatric comorbidity among alcohol-dependent individuals seeking treatment at the Alcohol Rehabilitation Unit, Stikla
• ^[3] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[5] → ^[4] (verifier: yes; score 0.76). Title: _An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive _
• ^[19] → ^[5] (verifier: partial; score 0.85). Title: Adult mental health outcomes of adolescent depression and co-occurring alcohol use disorder: a longitudinal cohort study
• ^[7] → ^[6] (verifier: partial; score 0.74). Title: Species differences in comorbid alcohol use disorder and major depressive disorder: A narrative review.
• ^[7] → ^[20] (verifier: partial; score 0.69). Title: Treatment of the depressed alcoholic patient.
• ^[7] → ^[21] (verifier: partial; score 0.75). Title: Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-releas
• ^[7] → ^[21] (verifier: partial; score 0.84). Title: Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-releas
• ^[7] → NO REPLACEMENT FOUND (considered 3 candidates; none verified)
• ^[7] → ^[22] (verifier: partial; score 0.56). Title: Eligibility for interventions, co-occurrence and risk factors for unhealthy behaviours in patients consulting for routin
• ^[7] → NO REPLACEMENT FOUND (considered 3 candidates; none verified)
• ^[17] → ^[7] (verifier: partial; score 0.84). Title: Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders.
• ^[17] → ^[2] (verifier: partial; score 0.74). Title: Psychiatric comorbidity among alcohol-dependent individuals seeking treatment at the Alcohol Rehabilitation Unit, Stikla
• ^[23] → ^[7] (verifier: partial; score 0.82). Title: Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders.
• ^[23] → ^[4] (verifier: partial; score 0.64). Title: _An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive _
• ^[13] → ^[6] (verifier: partial; score 0.85). Title: Species differences in comorbid alcohol use disorder and major depressive disorder: A narrative review.
• ^[13] → ^[24] (verifier: partial; score 0.79). Title: Clinical characteristics and 6-month follow-up of adults with and without alcohol use disorder who self-harm.
• ^[13] → ^[25] (verifier: partial; score 0.76). Title: Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.
• ^[10] → NO REPLACEMENT FOUND (considered 5 candidates; none verified)
• ^[26] → ^[27] (verifier: partial; score 0.74). Title: Integrated treatment of depression and moderate to severe alcohol use disorder in women shows promise in routine alcohol
• ^[27] → ^[13] (verifier: partial; score 0.61). Title: Subgroups of anxiety and depression trajectories during early abstinence in alcohol use disorder.
• ^[28] → ^[17] (verifier: partial; score 0.81). Title: Changes in alcohol consumption reported on routine healthcare screenings are associated with changes in depression sympt
• ^[29] → ^[6] (verifier: partial; score 0.80). Title: Species differences in comorbid alcohol use disorder and major depressive disorder: A narrative review.